FDA approves blinatumomab for MRD-positive acute lymphoblastic leukemia |

                            
            Choose Speciality
              
Register

                         No new Notifications.

                          Profile

                          Change Password

                          Logout

Log In

Journal Updates

FDA approves blinatumomab for MRD-positive acute lymphoblastic leukemia

eMediNexus, 30 March 2018
548 Views
#Hematology #Nursing #Oncology #Pathology and Lab Medicine

The US FDA has expanded the approval of blinatumomab (Blincyto) to include the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), for patients in remission who still have minimal residual disease (MRD).